426 related articles for article (PubMed ID: 31089072)
1. Criteria, phenotypes and prevalence of polycystic ovary syndrome.
Belenkaia LV; Lazareva LM; Walker W; Lizneva DV; Suturina LV
Minerva Ginecol; 2019 Jun; 71(3):211-223. PubMed ID: 31089072
[TBL] [Abstract][Full Text] [Related]
2. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis.
Bozdag G; Mumusoglu S; Zengin D; Karabulut E; Yildiz BO
Hum Reprod; 2016 Dec; 31(12):2841-2855. PubMed ID: 27664216
[TBL] [Abstract][Full Text] [Related]
3. Criteria, prevalence, and phenotypes of polycystic ovary syndrome.
Lizneva D; Suturina L; Walker W; Brakta S; Gavrilova-Jordan L; Azziz R
Fertil Steril; 2016 Jul; 106(1):6-15. PubMed ID: 27233760
[TBL] [Abstract][Full Text] [Related]
4. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome.
Fraissinet A; Robin G; Pigny P; Lefebvre T; Catteau-Jonard S; Dewailly D
Hum Reprod; 2017 Aug; 32(8):1716-1722. PubMed ID: 28854589
[TBL] [Abstract][Full Text] [Related]
5. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis.
Lie Fong S; Laven JSE; Duhamel A; Dewailly D
Hum Reprod; 2017 Aug; 32(8):1723-1731. PubMed ID: 28854584
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.
Lauritsen MP; Bentzen JG; Pinborg A; Loft A; Forman JL; Thuesen LL; Cohen A; Hougaard DM; Nyboe Andersen A
Hum Reprod; 2014 Apr; 29(4):791-801. PubMed ID: 24435776
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria.
Yildiz BO; Bozdag G; Yapici Z; Esinler I; Yarali H
Hum Reprod; 2012 Oct; 27(10):3067-73. PubMed ID: 22777527
[TBL] [Abstract][Full Text] [Related]
8. Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles.
Dewailly D; Alebić MŠ; Duhamel A; Stojanović N
Hum Reprod; 2014 Nov; 29(11):2536-43. PubMed ID: 25267785
[TBL] [Abstract][Full Text] [Related]
9. [Current diagnosis of polycystic ovary syndrome: expanding the phenotype but generating new questions].
Merino P; Schulin-Zeuthen C; Codner E
Rev Med Chil; 2009 Aug; 137(8):1071-80. PubMed ID: 19915773
[TBL] [Abstract][Full Text] [Related]
10. High Prevalence of Polycystic Ovary Syndrome in Type 1 Diabetes Mellitus Adolescents: Is There a Difference Depending on the NIH and Rotterdam Criteria?
Busiah K; Colmenares A; Bidet M; Tubiana-Rufi N; Levy-Marchal C; Delcroix C; Jacquin P; Martin D; Benadjaoud L; Jacqz-Aigrain E; Laborde K; Robert JJ; Samara-Boustani D; Polak M
Horm Res Paediatr; 2017; 87(5):333-341. PubMed ID: 28437788
[TBL] [Abstract][Full Text] [Related]
11. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.
Azziz R
J Clin Endocrinol Metab; 2006 Mar; 91(3):781-5. PubMed ID: 16418211
[TBL] [Abstract][Full Text] [Related]
12. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society.
Dewailly D; Lujan ME; Carmina E; Cedars MI; Laven J; Norman RJ; Escobar-Morreale HF
Hum Reprod Update; 2014; 20(3):334-52. PubMed ID: 24345633
[TBL] [Abstract][Full Text] [Related]
13. Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis.
Skiba MA; Islam RM; Bell RJ; Davis SR
Hum Reprod Update; 2018 Nov; 24(6):694-709. PubMed ID: 30059968
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of polycystic ovary syndrome.
Trivax B; Azziz R
Clin Obstet Gynecol; 2007 Mar; 50(1):168-77. PubMed ID: 17304034
[TBL] [Abstract][Full Text] [Related]
15. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis.
Lizneva D; Kirubakaran R; Mykhalchenko K; Suturina L; Chernukha G; Diamond MP; Azziz R
Fertil Steril; 2016 Nov; 106(6):1510-1520.e2. PubMed ID: 27530062
[TBL] [Abstract][Full Text] [Related]
16. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?
Eilertsen TB; Vanky E; Carlsen SM
Hum Reprod; 2012 Aug; 27(8):2494-502. PubMed ID: 22693172
[TBL] [Abstract][Full Text] [Related]
17. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria.
Kauffman RP; Baker TE; Baker VM; DiMarino P; Castracane VD
Am J Obstet Gynecol; 2008 Jun; 198(6):670.e1-7; discussion 670.e7-10. PubMed ID: 18355776
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome.
Goodarzi MO; Azziz R
Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):193-205. PubMed ID: 16772151
[TBL] [Abstract][Full Text] [Related]
19. The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome.
Alebić MŠ; Stojanović N; Duhamel A; Dewailly D
Hum Reprod; 2015 Aug; 30(8):1927-33. PubMed ID: 26048913
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.
March WA; Moore VM; Willson KJ; Phillips DI; Norman RJ; Davies MJ
Hum Reprod; 2010 Feb; 25(2):544-51. PubMed ID: 19910321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]